Fiala

Peptide library › Bone health

Palopegteriparatide

Also known as Yorvipath, TransCon PTH

FDA-approved drugBone health

Daily long-acting parathyroid hormone replacement for adults with hypoparathyroidism.

What people use it for

What Palopegteriparatide does in the body

A prodrug that slowly releases the active part of parathyroid hormone, PTH(1-34), giving steady levels through the day. This keeps blood calcium normal without large doses of calcium and vitamin D.

Strength of evidence

Strong: the Phase 3 PaTHway trial kept calcium normal in most people without standard supplements.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2024, after earlier approval in Europe. Prescription only.

How it's taken

Route: Injection under the skin, once daily

How long it lasts (half-life): About 60 hours for the released hormone

Storage

Refrigerated before first use; then follow the pen instructions.

Keep track of Palopegteriparatide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Palopegteriparatide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Bone health